Human PD-L1 / B7-H1 / CD274 Protein (His Tag) 10084-H08H from Sino Biological, Inc.

Product Specs
ItemHuman PD-L1 / B7-H1 / CD274 Protein (His Tag)
CompanySino Biological, Inc.
Price $2,148.00Supplier Page View Company Product Page
Catalog Number10084-H08H
Size1 mg
Conjugate/TagC-His
Purity≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC. ≥ 95 % as determined by SEC-MALS(Routinely tested)
TypeRecombinant protein
Molecular WeightThe recombinant mature human B7-H1 comprises 232 amino acids and predicts a molecular mass of 26.8 kDa. As a result of glycosylation, the human B7-H1 migrates as an approximately 35-38 kDa protein in SDS-PAGE under reducing conditions. The molecular weight of this protein is around 32.7 kDa verified by SEC-MALS(Routinely tested)
SpeciesHuman
Molecule NameCD274
Source/Expression SystemHEK293 Cells
Activity1.Immobilized Anti-PDL1(GEN)-IgG1 Antibody (Atezolizumab) at 2 µg/mL (100 µL/well) can bind Recombinant Human PD-L1 / B7-H1 / CD274 Protein (His Tag) (Cat:10084-H08H), the EC50 is 0.7-2.1 ng/mL（ Routinely tested ）. 2. Loaded Recombinant Human PD-1 Protein, hFc Tag (Cat. No. 10377-H02H) on ProA Biosensor, can bind Recombinant Human PD-L1/B7-H1 Protein, his Tag (Cat. No. 10084-H08H) with an affinity constant of 1.4 µM as determined in BLI assay (Sartorius Octet RED384) (Routinely tested). 3.Captured Anti-PD-L1 Mab (Human IgG1) on proA Chip can bind PD-L1 (Cat.No.10084-H08H) with an affinity constant of 1.381nM as determined in a SPR assay (Biacore T200) (Routinely tested). 4.Recombinant Human PD-1 Protein, hFc Tag (Cat. No. 10377-H02H) captured on Protein A chip, can bind Recombinant Human PD-L1/B7-H1 Protein, His Tag (Cat. No. 10084-H08H) with an affinity constant of 1.620 µM as determined in an SPR assay (Biacore 8K) (Routinely tested). 5.Immobilized Recombinant Human PD-L1 / B7-H1 / CD274 Protein (His Tag)(Cat: 10084-H08H) at 1 µg/mL (100 µL/well) can bind Anti-PDL1 (Research Grade Atezolizu*mab Biosimilar), the EC50 is 0.8-3.5 ng/mL (QC tested). 6.Immobilized Recombinant Human PD-L1 / B7-H1 / CD274 Protein (His Tag)(Cat: 10084-H08H) at series of concentration on MonoRabᵀᴹ Anti-His Tag (C-term) Antibody precoated (0.1ug/well) plate, can bind Recombinant Human PD1 / PDCD1 / CD279 Protein (ECD, Fc Tag) (Cat: 10377-H05H) at 5 µg/mL (100 µL/well), the EC50 is 6.94ng/mL (Routinely tested)
FormatLyophilized from sterile PBS, pH 7.4

Add to Compare List

Sino Biological, Inc.

37 Industrial Blvd

Suite B

Paoli, PA 19301

United States

Phone: 215-583-7898
Fax: 267-657-0217

Email: marketing@sinobiological.com

Company Profile

Website: sinobiological.com

(1) Design, synthesis and activity evaluation of tetrahydroisoquinoline-based programmed cell death ligand 1 inhibitorsSmart MolJuly 28, 2026Menglin Yu, Sen Cai, Yanyan Pan, Heshuang Wang, Fengwu Zhang, Aiyu Ma, Shixuan Lv, Xiuhan Guo, Shisheng Wang, Qiling Song, et al.compounds to hPD‐L1 protein were assessed by a SPR assay. Briefly, The PD‐L1 protein(Sino Biological Inc:10084‐H08H) was diluted to 200 μg/mL with sodium acetate buffer (pH 4.5), then immobilized on a CM5 sensor chip

(2) A Bead‐Based Screening Platform for Identifying Monoclonal Antibodies That Disrupt PD‐1/PD‐L1 InteractionsJournal of Immunology ResearchMarch 31, 2026Veridiane M. Pscheidt, Rodrigo B. Gassen, José E. Sacconi Nunes, Deise do Nascimento de de Freitas, Valdir Barth, Fernanda B. Frozza, Milena D. Santos, Claudia P. Nunes, Cristina B. C. BonorinoProtein Labeling With Fluorescence Alexa Fluor 488 (AF 488) conjugation with human PD‐L1 protein (Cat. #10084‐H08H, Sino Biological) was performed using a commercial Alexa Fluor 488 carboxylic acid tetrafluorophenyl

(3) PD1-induced Shp2 condensation organizes inhibitory signalosomes through selective substrate partitioningbioRxivMarch 14, 2026Takeya Masubuchi, George A Wen, Xiaoxian Song, Keshav Gaddam, Haian Shao, Chuan Wu, Enfu HuiInvitrogen. BSA (Bovine Serum Albumin, #A-420-1) was purchased from Goldbio. Recombinant proteins hPDL1-His (#10084-H08H), hICAM-1 (#10346-H08H), hCD86-His (#10699-H08H), and hPVR-His (#10109-H08H) were purchased from Sino Biological

(4) PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer ImmunotherapyAdvanced ScienceFebruary 11, 2026Huixin Gao, Lijuan Lu, Xiaoxiao Xiong, Yi Li, Donghui Hu, Duo Zhang, Zhiwei Feng, Cong Liu, Nannan Liu, Xiaoli Li, et al.Detection of PBAP‐HER2: 96‐well plates were coated with 2 µg/mL human PD‐L1 (ECD, His Tag, SinoBiological, 10084‐H08H) protein in carbonate buffer overnight at 2°C–8°C. The next day, the plates were blocked with 2% BSA

(5) IMM2510, a novel anti-PD-L1/VEGF bispecific antibody for cancer immunotherapyAntibody TherapeuticsJanuary 15, 2026Dianze Chen, Zhuli Wu, Xiwen Zhao, Rupal S Bhatt, Yanan Yang, Wenqi Zhu, Huang Tang, Kaili Wang, Chunli Guo, Dandan Liu, et al.Cat#50159-HNAB), Rat VEGFA (Sino Biological, Cat#80006-RNAB), Human PD-L1 His (Sino Biological, Cat#10084-H08H), Human PD-L2 His (Sino Biological, Cat#10292-H08H), Cynomolgus PD-L1 His (Sino Biological, Cat#90251-C08H),

(6) De novo design of epitope-specific antibodies via a structure-driven computational workflowNature CommunicationsDecember 10, 2025Fandi Wu, Yu Zhao, JiaXiang Wu, Biaobin Jiang, Bing He, Longkai Huang, Chenchen Qin, Yang Xiao, Fan Yang, Rubo Wang, et al.the PD-L1/PD-1 binding interface to disrupt this immunosuppressive interaction. (Sino Biological, REF:10084-H08H). SARS-CoV-2 spike protein receptor-binding domain (SC2RBD), a protein domain required for COVID-19

(7) IGM-7354, an Immunocytokine with IL15 Fused to an Anti-PD-L1 IgM, Induces NK and CD8+ T cell-Mediated Cytotoxicity of PD-L1-Positive Tumor CellsCancer immunology researchAugust 1, 2025Desbois M, Giffon T, Yakkundi P, Denson CR, Sekar K, Hart KC, Santos D, Calhoun SE, Logronio K, Pandey S, et al.Webster mice were immunized subcutaneously with human and cynomolgus monkey PD-L1-His (Sino Biological, #10084-H08H and #90251-C08H) along with Magic Mouse adjuvant (Creative Diagnostics, #CDN-A001), and splenocyte fusions

(8) A novel therapeutic approach targeting PD-L1 in HNSCC and bone marrow-derived mesenchymal stem cells hampers pro-metastatic features in vitro: perspectives for blocking tumor-stroma communication and signalingCell Commun SignalFebruary 10, 2025Ylenia Ferrara, Debora Latino, Angela Costagliola di Polidoro, Angela Oliver, Annachiara Sarnella, Maria Grazia Caprio, Laura Cerchia, Menotti Ruvo, Annamaria Sandomenico, Antonella Zannetti(SPR) The recombinant Fab’ was tested for its ability to bind the target antigen rhPD-L1 protein (10084-H08H, Sinobiological) performing real-time binding assays by Surface Plasmon Resonance using CM5 sensor chips

(9) Functional differences between rodent and human PD-1 linked to evolutionary divergenceScience immunologyJanuary 3, 2025Masubuchi T, Chen L, Marcel N, Wen GA, Caron C, Zhang J, Zhao Y, Morris GP, Chen X, Hedrick SM, et al.(#A-420-1) was purchased from Goldbio. Recombinant protein huPD-1-His (#10377-H08H), huPD-L1-His (#10084-H08H), moPD-1-His (#50124-M08H), moPDL1-His (#50010-M08H), huICAM-1 (#10346-H08H), and moICAM-1 (#50440-M08H)

(10) Construction and preclinical evaluation of a (124)I-labelled bispecific antibody targeting PD-L1 and PD-L2European journal of nuclear medicine and molecular imagingDecember 1, 2024Yao Y, Ren Y, Hou X, Wang P, Zhu J, Liu S, Ma X, Liu T, Yang Z, Zhu H, et al.

(11) Discovery of Daclatasvir as a potential PD-L1 inhibitor from drug repurposingBioorganic chemistryDecember 1, 2024Sun M, Lv S, Pan Y, Song Q, Ma C, Yu M, Gao X, Guo X, Wang S, Gao Z, et al.

(12) IMM2520, a novel anti-CD47/PD-L1 bispecific antibody for cancer immune therapyHeliyonNovember 15, 2024Chunmei Yang, Song Li, Dianze Chen, Dandan Liu, Yanan Yang, Huiqin Guo, Nana Sun, Xing Bai, Guanghui Li, Ruliang Zhang, et al.Probe loading was conducted for 120 s utilizing a concentration of 10 μg/mL His-tag PD-L1 antigen (Cat#10084-H08H; Sino Biological) or mFc-tag CD47 antigen (in-house).The subsequent step involved washing the probe

(13) In situ editing of tumour cell membranes induces aggregation and capture of PD-L1 membrane proteins for enhanced cancer immunotherapyNature communicationsNovember 9, 2024Mao C, Deng F, Zhu W, Xie L, Wang Y, Li G, Huang X, Wang J, Song Y, Zeng P, et al.

(14) A Novel Monoclonal Antibody against PD-1 for the Treatment of Viral Oncogene-Induced Tumors or Other CancerCancersSeptember 1, 2024Xu X, Yan SL, Yo YT, Chiang P, Tsai CY, Lin LL, Qin A.Assessment of Binding Specificity Antigens including human PD-L1 (Sino Biological, Beijing, China, 10084-H08H), human PD-L2 (Sino Biological, 10292-H08H), human CTLA-4 (Sino Biological, 11159-H08H), human CD28

(15) Preclinical development of novel PD-L1 tracers and first-in-human study of [(68)Ga]Ga-NOTA-RW102 in patients with lung cancersJournal for immunotherapy of cancerApril 5, 2024Zhang Y, Cao M, Wu Y, Malih S, Xu D, Yang E, Younis MH, Lin W, Zhao H, Wang C, et al.RW102 and ABDRW102 A healthy alpaca was immunized with 2 mg of recombinant human PD-L1 protein (Cat: 10084-H08H; Sino Biological) mixed with an equal volume of Freund’s complete adjuvant six times. Meanwhile, the

(16) Establishment of novel anti-TIM-3 antibodies interfering with its binding to ligandsHeliyonMarch 18, 2024Zhuohong Yan, Teng Ma, Xiaojue Wang, Ling Yi, Panjian Wei, Hongtao Zhang, Jinghui WangSino Biological, 10041-H08H), OX40-His (hOX40; Sino Biological, 10481-H08H), PD-L1-His (hPD-L1; Sino Biological, 10084-H08H), mouse TIM-3-His (mTIM-3; Sino Biological, 51152-M08H), or cynomolgus TIM-3-hFc (cynTIM-3; Sino Biological,

(17) PD-L1 targeted peptide demonstrates potent antitumor and immunomodulatory activity in cancer immunotherapyFrontiers in immunologyJanuary 1, 2024Liang Y, Luo H, Li X, Liu S, Habib A, Liu B, Huang J, Wang J, Yi H, Hu B, et al.rabbit anti-human PD-1 antibody (Clone D67, Cat: 10377-RD67), recombinant human PD-L1 protein (Cat: 10084-H08H), human PD-L1/B7-H1/CD274 protein (Cat: 10084-HNAH), biotinylated mouse PD-1/PDCD1 protein (His tag)

(18) Resistance to anti-PD-1/anti-PD-L1: galectin-3 inhibition with GB1211 reverses galectin-3-induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1Frontiers in ImmunologyAugust 28, 2023Joseph Mabbitt, Ian D. Holyer, James A. Roper, Ulf J. Nilsson, Fredrik R. Zetterberg, Lynda Vuong, Alison C. Mackinnon, Anders Pedersen, Robert J. Slackwith or without combined treatment with an anti-PD-L1 blocking antibody. Methods Materials PD-1 (10084-H08H) and PD-L1 (10377-H08H) human recombinant proteins were purchased from Sino Biological (China). Jurkat-Lucia™

(19) Identification of CBPA as a New Inhibitor of PD-1/PD-L1 InteractionInternational journal of molecular sciencesFebruary 16, 2023Wang F, Ye W, He Y, Zhong H, Zhu Y, Han J, Gong X, Tian Y, Wang Y, Wang S, et al.the negative control; tube 2: 50 µL commercially available recombinant hPD-L1-His protein (10 ug/mL, 10084-H08H, Sino Biological) + 50 µL PBS as the positive control; tube 3: 50 µL PD-L1-His protein + 50 µL 40 µM

(20) The RESP AI model accelerates the identification of tight-binding antibodiesNature communicationsJanuary 28, 2023Parkinson J, Hard R, Wang W.10084-H08H-B) 3 hrs at RT in TBS-BSA, followed by incubation with excess non-biotin-PD-L1 (Sino Biological 10084-H08H) for the determined competition period (at RT, in TBS-BSA). For FACS, yeasts were labeled with anti-V5

Be the First to Write a Review!

Human PD-L1 / B7-H1 / CD274 Protein (His Tag)

Human PD-L1 / B7-H1 / CD274 Protein (His Tag) from Sino Biological, Inc.

Description

Sino Biological, Inc.

Citations (49)

Reviews

Human PD-L1 / B7-H1 / CD274 Protein (His Tag) from Sino Biological, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map